Gilead raises its sales outlook by $900 million, but its loss forecast gets worse

Gilead raised its full-year product-sales outlook by $900 million on October 29 after a strong quarter for HIV medicines. At the same time, it widened both its GAAP and non-GAAP forecasts for a full-year loss. The two developments belong in the same headline: higher medicine sales are improving the operating business while acquisition-related charges weigh heavily on the year’s reported earnings.

The company now expects 2026 product sales of $31 billion to $31.3 billion, compared with its August range of $30.1 billion to $30.4 billion. The midpoint rises from $30.25 billion to $31.15 billion, an increase of about 3%. Excluding COVID-19 treatment Veklury, the sales range also rises by $900 million at both ends.

Sales guidance and earnings guidance point in different directions

Gilead’s official results now project a GAAP diluted loss of $4.05 to $4.40 per share for the year, compared with the previous expected loss of $3.40 to $3.75. The loss midpoint therefore deteriorates by 65 cents, from about $3.58 to about $4.23 a share.

The non-GAAP range also worsens: a loss of 85 cents to $1.20 per share, compared with a prior forecast loss of 30 cents to 65 cents. Its midpoint deteriorates by 55 cents. Adjusted earnings are not a shortcut around every acquisition expense in this release, and treating the non-GAAP label as meaning “before all deal costs” would miss an important part of the disclosure.

Gilead says both guidance measures include an approximately $9.88-per-share impact associated with $12.4 billion in acquired in-process research and development charges from the Arcellx, Tubulis, Ouro Medicines and PepStar transactions announced this year, net of the Lakefront collaboration and related taxes. That disclosure explains the scale of the acquisition effect; it does not mean the full-year loss range can simply be replaced with an invented “underlying” profit forecast.

Buying a development-stage program creates a different timing pattern from selling an established medicine. A large research charge can arrive before the acquired program generates commercial sales, while success, approval and future returns remain uncertain. The near-term loss forecast is consequently not a direct measure of whether demand for Gilead’s existing HIV drugs has improved.

The operating growth is substantial, but its ingredients matter

Third-quarter product sales rose 13% to $8.3 billion. Excluding Veklury, they increased 16% to $8.2 billion. HIV product sales grew 18% to $6.2 billion, helped by higher realized prices, prevention demand and favorable inventory dynamics. Those three drivers should not be collapsed into a claim that patient volumes alone grew 18%.

Biktarvy sales increased 10% to $4.1 billion. Descovy sales rose 49% to about $1 billion, with the company pointing primarily to realized prices and inventory effects. Calculated from the rounded figures, Biktarvy represented roughly 49% of total product sales and about two-thirds of HIV sales. The concentration makes its pricing and competitive outlook material even as newer products grow faster.

Trodelvy sales increased 42% to $506 million, while liver-disease portfolio sales rose 13% to $927 million. There were meaningful weak spots: cell-therapy sales declined 18% to $355 million, and Veklury sales fell 69% to $86 million as COVID-19 hospitalization rates declined. A strong overall quarter did not mean every franchise was expanding.

Product gross margin improved to 81% from 78.6%, a 2.4-percentage-point increase. Gilead attributes that improvement primarily to the expiration of a royalty-related obligation. That is a useful counterweight to a simplistic pricing explanation: some of the better profitability came from a lower obligation attached to sales, rather than an across-the-board reduction in research or commercial spending.

Why quarterly profit fell despite the stronger business

Quarterly GAAP diluted earnings fell to $1.94 a share from $2.43, a decline of approximately 20.2%. Non-GAAP diluted earnings rose to $2.55 from $2.47, about 3.2%. The company identifies equity-security losses versus prior-year gains, higher operating expenses, taxes and lower royalty, contract and other revenue among the pressures on GAAP earnings.

Research and development expenses increased to $1.6 billion from $1.3 billion. GAAP selling, general and administrative expenses rose to $1.6 billion from $1.4 billion. HIV promotion, acquisition integration, legal matters and employee costs contributed to the latter increase. These disclosures complicate the view that the sales acceleration immediately drops through to shareholders.

Cash generation was nevertheless strong: Gilead produced $5 billion in operating cash flow during the quarter and $11.2 billion in the first nine months. Cash, cash equivalents and marketable debt securities fell to $6.4 billion at September 30 from $10.6 billion at the end of 2025, a decline of $4.2 billion, or about 39.6%.

The cash movement reflects capital allocation, not just operating weakness. Year-to-date outflows included $11.3 billion for acquisitions, $2.8 billion in debt repayments, $3.1 billion in dividends and $1.1 billion in repurchases, partly offset by operating cash flow and $4.1 billion in net debt-financing proceeds. Those rounded amounts are a funding map, not a complete cash-flow reconciliation.

The dates that matter beyond this quarter

Gilead says Medicare completed the process of setting Biktarvy’s Maximum Fair Price in October. The new price begins affecting Biktarvy revenue on January 1, 2028. The release does not quantify the resulting revenue reduction, so the size of that effect should not be guessed from the drug’s current quarterly sales.

For patients and providers, commercial growth is distinct from eligibility, availability and the price an individual pays. The earnings release is not evidence that every prevention patient has obtained access or that acquisition spending guarantees a successful new therapy. Gilead also plans to begin a Phase 3 ulcerative-colitis study of investigational emvistegrast in 2027, another development milestone rather than an approved product launch.

For shareholders, the nearer dated cash-return event is the declared 82-cent dividend, payable December 30 to holders of record December 15. Beyond that, the central test is whether growth in established products can support the investment program while the acquired pipeline advances. This quarter supplies evidence for a stronger commercial business. The larger loss guidance shows why that is only one side of the company’s investment case.